OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
The new plant will manufacture high-quality Type I borosilicate glass tubing
First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Subscribe To Our Newsletter & Stay Updated
